Rosenbloom: Curb PBMs’ power
By Alan Rosenbloom
Letter to the Editor
The Washington Times
Despite the purported value of pharmacy benefit managers (PBMs), drug prices remain unaffordable for many Americans (“Prescription drug pricing reform must rein in pharmacy benefit managers,” Web, Oct. 18). As middlemen between the manufacturers, pharmacies and consumers, PBMs are notorious for abusive business practices that impact both patients’ wallets and their access to prescription drugs, while gouging unaffiliated pharmacies.
As Rep. Carter and Mr. Wilcox correctly note, PBMs process the vast majority of the nation’s prescription drugs. This undue concentration of market power means they can and do restrict consumer access to expensive drugs and cause delays in treatment, all so that affiliated pharmacies dispense and earn revenues while denying competing pharmacies access to high-margin drugs.
PBMs are not freestanding operations. They are part of huge health care conglomerates that dominate not only the PBM market, but a series of adjoining markets including health insurance, retail pharmacy, specialty pharmacy, mail-order pharmacy and long-term-care pharmacy. They have also become health care providers, which has allowed them to control the flow of medications. This anti-competitive behavior is clearly apparent in Express Scripts’ recent decision to reduce reimbursement rates for pharmacies in the TRICARE network, forcing veterans and their families to find alternate ways to access covered drugs — or simply pay for them out-of-pocket.
Small businesses, such as the community and long-term care pharmacies that are not part of these corporate behemoths, deserve protection from unfair trade practices. Consumers deserve more than the illusion of low costs at the price of easy access to essential medications.
To curb PBMs’ exploitative business practices, all stakeholders — including the Federal Trade Commission, Congress, the Biden administration and federal health departments — must focus on how these entities drive high drug prices, restrict access to essential medications and threaten unaffiliated pharmacies.
To view the original article click here.
Recent Posts
-
Rep. Van Duyne Introduces Bipartisan Legislation to Protect Seniors’ Access to Long-Term Care Pharmacies
Washington, D.C. – Representatives Beth Van Duyne (R-TX), Brad Schneider (D-IL), Buddy Carter (R-GA), Sharice Davids (D-KS), and Deborah Ross (D-NC) introduced H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act, bipartisan legislation to protect access to essential medications and pharmacy services for seniors and other long-term care (LTC) residents in nursing homes, assisted living, and similar […]
-
SCPC Applauds Introduction of Preserving Patient Access to Long-Term Care Pharmacies Act (H.R. 5031) to Ensure Seniors’ Access to Essential Meds and Pharmacy Services
SCPC Applauds Introduction of Preserving Patient Access to Long-Term Care Pharmacies Act (H.R. 5031) to Ensure Seniors’ Access to Essential Meds and Pharmacy Services
-
Senior Care Pharmacy Coalition Releases Statement in Support of Rep. Buddy Carter’s New Bipartisan PBM Reform Package
The Senior Care Pharmacy Coalition (SCPC), the leading voice for the nation’s long-term care (LTC) pharmacy community, released the following statement in support of Congressman Buddy Carter’s (R-GA) new bipartisan PBM reform package, the PBM Reform Act. This important bill would finally protect patients and pharmacies from the harmful and anticompetitive business practices of pharmacy benefit managers (PBMs).
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.